<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>BARDA</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Moderna to pay up to $2.25B to settle COVID-19 patents case</title>
      <description>
        <![CDATA[In what it says could be the largest disclosed patent settlement in the pharmaceutical industry, Roivant Sciences Ltd. has reached a potential $2.25 billion settlement with Moderna Inc. over the use of its lipid nanoparticle delivery technology in the Spikevax COVID-19 vaccine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729387</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729387-moderna-to-pay-up-to-225b-to-settle-covid-19-patents-case</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Moderna-Spikevax-9-2.webp?t=1772645697" type="image/jpeg" medium="image" fileSize="152907">
        <media:title type="plain">Spikevax vial and product packaging</media:title>
        <media:description type="plain">Credit: Moderna Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>BARDA offers $100M in prize money for antiviral development</title>
      <description>
        <![CDATA[Looking to fill a treatment gap, the U.S. Biomedical Advanced Research and Development Authority (BARDA) is launching the first stage of a $100 million prize competition to support development of broad-spectrum, small-molecule antiviral therapies targeting viruses in the <em>Togaviridae </em>and<em> Flaviviridae</em> families.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728696</guid>
      <pubDate>Wed, 04 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728696-barda-offers-100m-in-prize-money-for-antiviral-development</link>
    </item>
    <item>
      <title>BARDA offers $100M in prize money for antiviral development</title>
      <description>
        <![CDATA[Looking to fill a treatment gap, the U.S. Biomedical Advanced Research and Development Authority (BARDA) is launching the first stage of a $100 million prize competition to support development of broad-spectrum, small-molecule antiviral therapies targeting viruses in the <em>Togaviridae </em>and<em> Flaviviridae</em> families.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728675</guid>
      <pubDate>Wed, 04 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728675-barda-offers-100m-in-prize-money-for-antiviral-development</link>
    </item>
    <item>
      <title>Pandemic-era nonprofit funding fades from biopharma in 2025</title>
      <description>
        <![CDATA[The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127.43 million in 2025 after exceeding $21.4 billion in 2021. The 2025 total also represents a steep drop from 2024’s $754.56 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727983</guid>
      <pubDate>Tue, 13 Jan 2026 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727983-pandemic-era-nonprofit-funding-fades-from-biopharma-in-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Pandemic-era nonprofit funding fades from biopharma in 2025</title>
      <description>
        <![CDATA[The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127.43 million in 2025 after exceeding $21.4 billion in 2021. The 2025 total also represents a steep drop from 2024’s $754.56 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727764</guid>
      <pubDate>Thu, 08 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727764-pandemic-era-nonprofit-funding-fades-from-biopharma-in-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma nonprofit dealmaking and grants stabilize in a new normal</title>
      <description>
        <![CDATA[Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725899</guid>
      <pubDate>Tue, 04 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725899-biopharma-nonprofit-dealmaking-and-grants-stabilize-in-a-new-normal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma nonprofit dealmaking and grants stabilize in a new normal</title>
      <description>
        <![CDATA[Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725777</guid>
      <pubDate>Mon, 03 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725777-biopharma-nonprofit-dealmaking-and-grants-stabilize-in-a-new-normal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>France’s Osivax wins $19.5M BARDA award for universal flu vaccine</title>
      <description>
        <![CDATA[French vaccines specialist Osivax SAS has been awarded $19.5 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to fund work on its universal influenza A vaccine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723316</guid>
      <pubDate>Tue, 26 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723316-frances-osivax-wins-195m-barda-award-for-universal-flu-vaccine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Woman-receiving-vaccine.webp?t=1743630379" type="image/jpeg" medium="image" fileSize="84867">
        <media:title type="plain">Woman receiving vaccine</media:title>
      </media:content>
    </item>
    <item>
      <title>US HHS cancels 22 BARDA mRNA vaccine contracts</title>
      <description>
        <![CDATA[Cancel culture continues at the U.S. Department of Health and Human Services (HHS) as it observes National Immunization Awareness Month with another strike against vaccines. This time, a $500 million strike specifically targets 22 mRNA vaccine R&D programs at the Biomedical Advanced Research and Development Authority (BARDA), marking the beginning of the end of BARDA’s funding for mRNA vaccines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722809</guid>
      <pubDate>Wed, 06 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722809-us-hhs-cancels-22-barda-mrna-vaccine-contracts</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Gloved-hands-holding-mRNA-vaccine-vial.webp?t=1754515721" type="image/jpeg" medium="image" fileSize="437401">
        <media:title type="plain">Gloved hands holding mRNA vaccine vial</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO 2025: Building biosecurity through public-private partnership</title>
      <description>
        <![CDATA[The COVID-19 pandemic sent the world into a tailspin, raising ongoing concerns about biosecurity, a subject that encompassed the better part of the morning June 16, the first day of the Biotechnology Innovation Organization’s annual conference in Boston.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721312</guid>
      <pubDate>Mon, 16 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721312-bio-2025-building-biosecurity-through-public-private-partnership</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/DNA-strand-over-digital-lock-and-circuit-background.webp?t=1750110558" type="image/jpeg" medium="image" fileSize="519365">
        <media:title type="plain">DNA strand over digital lock and circuit background</media:title>
      </media:content>
    </item>
    <item>
      <title>US HHS awards Shionogi $375M to develop COVID-19 PrEP therapy</title>
      <description>
        <![CDATA[Shionogi & Co. Ltd. won a $375 million project agreement from the Rapid Response Partnership Vehicle to develop its 3CL protease inhibitor, S-892216, as a long-acting injectable for COVID-19 pre-exposure prophylaxis. The project was awarded to New Jersey-based Shionogi Inc., a subsidiary of the Osaka, Japan-based pharmaceutical company. S-892216 is an investigational second-generation 3CL protease inhibitor in development as a long-acting injectable for prophylaxis treatment of SARS-CoV-2.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716558</guid>
      <pubDate>Tue, 21 Jan 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716558-us-hhs-awards-shionogi-375m-to-develop-covid-19-prep-therapy</link>
    </item>
    <item>
      <title>Prepping for $1B in cuts, Moderna gets a $590M BARDA boost</title>
      <description>
        <![CDATA[While Moderna Inc. plans to cut its expenses by $1 billion in 2025, the company has received a little breathing room by a hefty U.S. Department of Health and Human Services (HHS) grant. The Biomedical Advanced Research and Development Authority awarded Moderna roughly $590 million to support late-stage development of its mRNA-based avian-variant vaccines and to increase the number of clinical trials for another five additional subtypes of pre-pandemic influenza.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716419</guid>
      <pubDate>Tue, 21 Jan 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716419-prepping-for-1b-in-cuts-moderna-gets-a-590m-barda-boost</link>
    </item>
    <item>
      <title>US HHS awards Shionogi $375M to develop COVID-19 PrEP therapy</title>
      <description>
        <![CDATA[Shionogi & Co. Ltd. won a $375 million project agreement from the Rapid Response Partnership Vehicle to develop its 3CL protease inhibitor, S-892216, as a long-acting injectable for COVID-19 pre-exposure prophylaxis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716385</guid>
      <pubDate>Fri, 17 Jan 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716385-us-hhs-awards-shionogi-375m-to-develop-covid-19-prep-therapy</link>
    </item>
    <item>
      <title>Ipsen enters ADC space licensing Sutro’s ROR1 drug STRO-003</title>
      <description>
        <![CDATA[Jumping in for the first time to the hot antibody-drug conjugate (ADC) space, Paris-based Ipsen SA pulled in exclusive global rights to a preclinical ROR1-targeting candidate from Sutro Biopharma Inc. in a deal worth up to $900 million. STRO-003, the first ADC to join Ipsen’s portfolio, contains an anti-ROR1 human IgG1 antibody (SP-11385) conjugated to an exatecan warhead, or payload.]]>
      </description>
      <guid>http://www.bioworld.com/articles/707094</guid>
      <pubDate>Tue, 02 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707094-ipsen-enters-adc-space-licensing-sutros-ror1-drug-stro-003</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/ADC-antibody-drug-conjugate-green.webp?t=1706306980" type="image/jpeg" medium="image" fileSize="182154">
        <media:title type="plain">3D rendering of drug linked to antibody</media:title>
      </media:content>
    </item>
    <item>
      <title>Post-pandemic COVID-19 era focuses on boosters, new strains</title>
      <description>
        <![CDATA[The official end of the COVID-19 public health emergency in the U.S. in May did not mark the end of interest and investment in the area. In the shifting landscape, attention has pivoted to new markets, emerging strains, boosters, and the commercialization and distribution of COVID-19 vaccines and therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701950</guid>
      <pubDate>Tue, 17 Oct 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701950-post-pandemic-covid-19-era-focuses-on-boosters-new-strains</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-gray-and-white.webp?t=1672954760" type="image/png" medium="image" fileSize="212641">
        <media:title type="plain">Coronavirus gray and white</media:title>
      </media:content>
    </item>
    <item>
      <title>CSL’s Seqirus snags $30M contract with BARDA to develop pandemic avian flu vaccines</title>
      <description>
        <![CDATA[CSL Ltd. subsidiary Seqirus inked a $30.1 million deal with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop and evaluate two influenza A subtype H2Nx (avian flu) vaccines in a phase I trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/690488</guid>
      <pubDate>Tue, 11 Oct 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690488-csls-seqirus-snags-30m-contract-with-barda-to-develop-pandemic-avian-flu-vaccines</link>
    </item>
    <item>
      <title>CSL’s Seqirus snags $30M contract with BARDA to develop pandemic avian flu vaccines</title>
      <description>
        <![CDATA[CSL Ltd. subsidiary Seqirus inked a $30.1 million deal with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop and evaluate two influenza A subtype H2Nx (avian flu) vaccines in a phase I trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/690433</guid>
      <pubDate>Mon, 10 Oct 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690433-csls-seqirus-snags-30m-contract-with-barda-to-develop-pandemic-avian-flu-vaccines</link>
    </item>
    <item>
      <title>BARDA award supports Arcturus' development of pandemic influenza vaccine</title>
      <description>
        <![CDATA[Arcturus Therapeutics Inc. has obtained an award for up to US$63.2 million from the Biomedical Advanced Research and Development Authority (BARDA) to expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/687406</guid>
      <pubDate>Thu, 01 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/687406-barda-award-supports-arcturus-development-of-pandemic-influenza-vaccine</link>
    </item>
    <item>
      <title>T2 activates plans for biothreat and resistance panels</title>
      <description>
        <![CDATA[T2 Biosystems Inc. is accelerating development of its T2biothreat and T2resistance panels, direct-from-blood panels that detect the six pathogens most likely to be weaponized and 13 common antibiotic resistance genes, respectively. A $4.4 million Biomedical Advanced Research and Development Authority (BARDA) cost-sharing contract will be used to advance clinical trials for the tests. The total potential funding from BARDA under the contract is $69 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/517542</guid>
      <pubDate>Fri, 01 Apr 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/517542-t2-activates-plans-for-biothreat-and-resistance-panels</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/04-01-T2-Bio-T2Dx-Instrument.webp?t=1648849370" type="image/png" medium="image" fileSize="272696">
        <media:title type="plain">T2dx instrument</media:title>
        <media:description type="plain">T2 Biosystems Inc.’s T2dx instrument</media:description>
      </media:content>
    </item>
    <item>
      <title>HHS settles whistleblower complaint with former BARDA director</title>
      <description>
        <![CDATA[Rick Bright, who filed a whistleblower complaint last year against the U.S. Department of Health and Human Services (HHS) after he was removed from his position as director of the Biomedical Advanced Research and Development Authority (BARDA), reached an undisclosed settlement with HHS, the U.S. Office of Special Counsel reported Aug. 9.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510279</guid>
      <pubDate>Tue, 10 Aug 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510279-hhs-settles-whistleblower-complaint-with-former-barda-director</link>
    </item>
    <item>
      <title>U.S. to invest $3.2B in COVID-19 antivirals R&amp;D, manufacturing</title>
      <description>
        <![CDATA[The U.S. government on June 17 announced plans for a multi-faceted $3.2 billion investment in the development and manufacture of new antivirals for preventing serious COVID-19 illness and death.]]>
      </description>
      <guid>http://www.bioworld.com/articles/508357</guid>
      <pubDate>Thu, 17 Jun 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/508357-us-to-invest-32b-in-covid-19-antivirals-rd-manufacturing</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibiotic-capsules-in-blister-packs.webp?t=1588278060" type="image/png" medium="image" fileSize="740755">
        <media:title type="plain">Capsules in blister packs</media:title>
      </media:content>
    </item>
    <item>
      <title>Mallinckrodt wins FDA nod for regenerative skin therapy for burns</title>
      <description>
        <![CDATA[More than four months after its original PDUFA date of Feb. 2, 2021, Mallinckrodt plc’s Stratagraft gained FDA approval for use in deep partial-thickness thermal burns. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/508262</guid>
      <pubDate>Wed, 16 Jun 2021 01:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/508262-mallinckrodt-wins-fda-nod-for-regenerative-skin-therapy-for-burns</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Stratagraft.webp?t=1623857407" type="image/png" medium="image" fileSize="489926">
        <media:title type="plain">Stratagraft</media:title>
        <media:description type="plain">Stratagraft, which comprises human keratinocytes and dermal fibroblasts in an engineered, bilayer construct, is designed to mimic natural human skin. Credit: Mallinckrodt plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Visby lands $12.3M for development of POC and consumer versions of combined rapid influenza/COVID-19 PCR test</title>
      <description>
        <![CDATA[Visby Medical Inc. secured $12.3 million in funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a next generation device to detect influenza and COVID-19 in a single point-of-care rapid PCR test and, subsequently, as an over-the-counter test for consumer use. The contract may be extended up to a total of $48.7 million over a period of 38 months based on meeting certain milestones in the base period, according to Visby Founder and CEO Adam de la Zerda.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503136</guid>
      <pubDate>Tue, 02 Feb 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503136-visby-lands-123m-for-development-of-poc-and-consumer-versions-of-combined-rapid-influenzacovid-19-pcr-test</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/02-02-Visby-device.webp?t=1612307761" type="image/png" medium="image" fileSize="390420">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">Point-of-care PCR test for COVID-19. Credit: Visby Medical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Ellume signs $231M supply agreement with U.S. government for COVID-19 home tests</title>
      <description>
        <![CDATA[PERTH, Australia &ndash;Digital diagnostics company Ellume Ltd. announced a US$231.8 million agreement with the U.S. Department of Defense (DoD), in coordination with the Department of Health and Human Services (HHS), to accelerate domestic U.S. production of its COVID-19 home tests. The agreement includes funding to support the establishment of Ellume&rsquo;s U.S.-based manufacturing facility and the delivery of 8.5 million COVID-19 home tests that will be distributed across the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503126</guid>
      <pubDate>Tue, 02 Feb 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503126-ellume-signs-231m-supply-agreement-with-us-government-for-covid-19-home-tests</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/02-02-Ellume-covid-home-test.webp?t=1612304011" type="image/png" medium="image" fileSize="389167">
        <media:title type="plain">Packaging and kit components</media:title>
        <media:description type="plain">Ellume COVID-19 home test. Credit: Ellume Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Decade of ‘Bank of BARDA’ under investigation</title>
      <description>
        <![CDATA[For at least the past decade – under both the Obama and Trump administrations, and perhaps even in previous administrations – the U.S. Department of Health and Human Services has been using the “Bank of BARDA” to routinely cover millions of dollars of unrelated spending at the Office of Assistant Secretary for Preparedness and Response, the U.S. Office of Special Counsel said in letters yesterday to President Joe Biden and Congress.]]>
      </description>
      <guid>http://www.bioworld.com/articles/502945</guid>
      <pubDate>Thu, 28 Jan 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/502945-decade-of-bank-of-barda-under-investigation</link>
    </item>
    <item>
      <title>European Commission president announces plan for EU version of BARDA</title>
      <description>
        <![CDATA[LONDON – The EU is to set up an equivalent to the U.S. Biomedical Advanced Research and Development Authority (BARDA), after coming under criticism from pharma companies about Europe’s inability to swiftly seal advance purchase agreements for COVID-19 vaccines. The plan was announced on Sept. 16 by European Commission President Ursula von der Leyen, in her first state of the union address since coming into office at the start of 2020. The new agency will support capacity and readiness to respond to cross-border health threats and emergencies, “whether of natural or deliberate origin,” she said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/497847</guid>
      <pubDate>Wed, 16 Sep 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/497847-european-commission-president-announces-plan-for-eu-version-of-barda</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/European-Commision-headquarters.webp?t=1652823141" type="image/png" medium="image" fileSize="456879">
        <media:title type="plain">European Commission headquarters</media:title>
        <media:description type="plain">European Commission headquarters in Brussels.
Credit: Mauro Bottaro</media:description>
      </media:content>
    </item>
    <item>
      <title>Moderna searches for the right participants in its phase III COVID-19 trial</title>
      <description>
        <![CDATA[Moderna Inc. dosed the first of what could be as many as 30,000 healthy volunteers Monday morning as it began its phase III COVID-19 vaccine trial. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/496264</guid>
      <pubDate>Mon, 27 Jul 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/496264-moderna-searches-for-the-right-participants-in-its-phase-iii-covid-19-trial</link>
    </item>
    <item>
      <title>Witnesses at Senate hearing press for annual appropriation for vaccine infrastructure</title>
      <description>
        <![CDATA[The Senate Health, Education, Labor and Pensions (HELP) Committee met again June 23 to discuss the federal government response to the COVID-19 pandemic, and one clear signal that emerged from the hearing is that Congress will have to provide annual funding to build a sustainable infrastructure for vaccine development and manufacture if the nation is to deal appropriately with the next pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436005</guid>
      <pubDate>Tue, 23 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436005-witnesses-at-senate-hearing-press-for-annual-appropriation-for-vaccine-infrastructure</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-Washington-congress-senate-house.webp?t=1588689130" type="image/png" medium="image" fileSize="1737899">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>Astrazeneca moving at Warp Speed with $1.2B in BARDA funding for COVID-19 vaccine</title>
      <description>
        <![CDATA[LONDON – Astrazeneca plc is to get up to $1.2 billion from the new U.S. COVID-19 vaccines program, Operation Warp Speed, to support further development and manufacturing of a vaccine developed at Oxford University’s Jenner Institute. The company said it will begin to ship the product in September 2020, with the U.K. and U.S. first in line for deliveries.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435263</guid>
      <pubDate>Thu, 21 May 2020 11:30:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435263-astrazeneca-moving-at-warp-speed-with-12b-in-barda-funding-for-covid-19-vaccine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Pandemic-vaccine.webp?t=1590079455" type="image/png" medium="image" fileSize="395824">
        <media:title type="plain">Scientist injecting vaccine into Earth</media:title>
      </media:content>
    </item>
    <item>
      <title>HHS-industry partnership to ramp up U.S.-based drug manufacturing</title>
      <description>
        <![CDATA[Responding to COVID-19’s wakeup call as it exposes the risks of relying heavily on foreign biopharma supply chains, the U.S. Department of Health and Human Services (HHS) signed a four-year, $354 million agreement with a team of private industry partners, led by Phlow Corp., to expand U.S. manufacturing of essential medicines at risk of shortage during the pandemic and in future public health emergencies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435213</guid>
      <pubDate>Tue, 19 May 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435213-hhs-industry-partnership-to-ramp-up-us-based-drug-manufacturing</link>
    </item>
  </channel>
</rss>
